[Federal Register Volume 78, Number 245 (Friday, December 20, 2013)]
[Notices]
[Page 77107]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-30367]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Notice of Availability for Exclusive, Non-Exclusive, or 
Partially-Exclusive Licensing of an Invention Concerning Antibody-
Dependent Cellular Cytoxicity (ADCC)-Mediating Antibodies

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Announcement is made of the availability for licensing of the 
invention set forth in U.S. Provisional Patent Application Serial No. 
61/762,543, entitled ``Antibody-Dependent Cellular Cytoxicity (ADCC)-
Mediating Antibodies,'' filed on February 8, 2013. The United States 
Government, as represented by the Secretary of the Army, has rights to 
this invention.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For patent issues, Ms. Elizabeth 
Arwine, Patent Attorney, (301) 619-7808. For licensing issues, Dr. Paul 
Mele, Office of Research and Technology Applications (ORTA), (301) 619-
6664, both at telefax (301) 619-5034.

SUPPLEMENTARY INFORMATION: The invention relates to Antibody-Dependent 
cellular cytoxicity (ADCC)-mediating antibodies, and, in particular, to 
ADCC-mediating antibodies (and fragments thereof) suitable for use, for 
example, in reducing the risk of HIV-1 infection in a subject. The 
invention further relates to compositions comprising such antibodies or 
antibody fragments.

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2013-30367 Filed 12-19-13; 8:45 am]
BILLING CODE 3710-08-P